AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, ...
ATLANTA (CN) - A federal judge dismissed the remaining claims in a nearly 10-year-old dispute over competition on AndroGel, a drug that boosts testosterone production. In the 1990s, Unimed ...
ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback